Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLR 121125

Next Previous
Drug Profile

CLR 121125

Alternative Names: (125)I-CLR-121125; 125-I-CLR-121125; CLR-121125; CLR-125; Iodine-125 CLR 121125 Auger emitting radiotherapeutic conjugate; Iodine-125-CLR-121125

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectar Biosciences
  • Class Antineoplastics; Drug conjugates; Iodine radioisotopes; Phospholipid ethers; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Triple negative breast cancer

Most Recent Events

  • 17 Feb 2026 Cellectar Biosciences has patent protection for CLR 125 covering therapeutic applications as well as its use for imaging and detection of primary tumors and cancer stem cells in Europe, China, Israel, Eurasia, and New Zealand
  • 07 Jan 2026 Phase-I clinical trials in Triple-negative-breast-cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT07311993)
  • 07 Oct 2025 Cellectar Biosciences announces intention to file Conditional Marketing Authorization (CMA) with the European Medicines Agency

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top